Utama › Glioma › North Carolina
Kajian klinikal Glioma di North Carolina
16 kajian untuk Glioma sedang mencari peserta di lokasi di North Carolina.
Bandar di North Carolina
Teks kajian rasmi (Bahasa Inggeris)
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
- Novant Health Presbyterian Medical Center, Charlotte
- East Carolina University, Greenville
- Wake Forest University Health Sciences, Winston-Salem
Mengambil pesertaFasa 1/2
12 Months – 21 Years · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05099003A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
Mengambil pesertaFasa 1/2
Sehingga umur 25 · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04094610ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Duke University Medical Center, Durham
Mengambil pesertaFasa 2
12 Months – 39 Years · Semua jantina · Dikemas kini 21 Sep 2026 · NCT06838676Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
Mengambil pesertaKajian pemerhatian
12 Months – 39 Years · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05839379Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
Mengambil pesertaFasa 2
Umur 12 hingga 39 · Semua jantina · Dikemas kini 1 Sep 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Ogo 2026 · NCT05303519ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
- Duke University Medical Center, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05609994PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
- Duke Cancer Center, Durham
Mengambil pesertaFasa 2
Umur 3 hingga 39 · Semua jantina · Dikemas kini 24 Ogo 2026 · NCT05096481MRI in High-Grade Glioma Patients Undergoing Chemoradiation
- Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 17 Ogo 2026 · NCT05212272A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center, Winston-Salem
Mengambil pesertaFasa 2
Umur 8 ke atas · Semua jantina · Dikemas kini 27 Jul 2026 · NCT05503797Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 20 Jul 2026 · NCT06177964Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
Mengambil pesertaFasa awal 1Sukarelawan sihat dialu-alukan
Umur 1 hingga 21 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Jun 2026 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
Mengambil pesertaFasa 2
12 Months – 39 Years · Semua jantina · Dikemas kini 29 Mei 2026 · NCT05843253Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
- Duke University, Durham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Apr 2026 · NCT06126744A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
- Duke University Health System, Durham
Mengambil pesertaFasa awal 1
Sehingga umur 21 · Semua jantina · Dikemas kini 18 Mac 2026 · NCT04655404Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.